

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/806,564	07/19/2001	Gunter Schmidt	P-0279469/20	1520
909 7:	590 01/23/2003			
PILLSBURY WINTHROP, LLP			EXAMINER	
P.O. BOX 10500 MCLEAN, VA 22102			LUKTON, DAVID	
			ART UNIT	PAPER NUMBER
			1653	2
		·	DATE MAILED: 01/23/2003	8

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No. 09/806,564

Applicant(s)

Examiner

David Lukton

Art Unit **1653**

Schmidt



The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
	for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>one</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the						
mailing - If the p - If NO p - Failure - Any rej	date of this communication. period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply at to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the control of t	e statutory minimun nd will expire SIX (6 e application to beco	n of thirty (30) MONTHS fr ome ABANDO)) days will be considered timely. om the mailing date of this communication. INED (35 U.S.C. § 133).		
Status	patent term adjustment. See 37 CFR 1.704(b).					
	Responsive to communication(s) filed on Nov 1, 20	002				
2a) 🗌	This action is FINAL . 2b) 🔀 This action	ion is non-fina	ıl.			
3) 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposit	tion of Claims					
4) 💢	Claim(s) 1-13 and 18-24			is/are pending in the application.		
4	a) Of the above, claim(s) 21 and 22	······································		is/are withdrawn from consideration.		
5) 🗆	Claim(s)			is/are allowed.		
6) 🗆	Claim(s)			is/are rejected.		
7) 🗌	Claim(s)			is/are objected to.		
8) 💢	Claims 1-13, 18-20, 23, and 24	ar	e subject	to restriction and/or election requirement.		
Applica	tion Papers					
9) 🗆	The specification is objected to by the Examiner.					
10)	The drawing(s) filed on is/are	a) accept	ed or b)	\Box objected to by the Examiner.		
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)	The proposed drawing correction filed on	is	s: a) □ a	pproved b) \square disapproved by the Examiner.		
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some* c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No					
;	 Copies of the certified copies of the priority do application from the International Burea 			ceived in this National Stage		
*Se	ee the attached detailed Office action for a list of the	e certified cop	ies not re	eceived.		
14) 🗆	Acknowledgement is made of a claim for domestic	priority under	35 U.S.0	C. § 119(e).		
a) The translation of the foreign language provisional application has been received.						
15)└┘	Acknowledgement is made of a claim for domestic	priority under	35 U.S.0	C. §§ 120 and/or 121.		
Attachme	ent(s) tice of References Cited (PTO-892)	4) 🔲 Intomious S	ummanı (PTC	-413) Paper No(s).		
_	tice of Draftsperson's Patent Drawing Review (PTO-948)	_		Application (PTO-152)		
_	3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)					

Applicants' election of Group I (claims 1-15) with traverse is acknowledged.

Pursuant to preliminary amendment, claims 14-17 have been cancelled, and cliams 18-24 Pursuant to applicants' election, claims added. Claims 1-13 and 18-24 are pending. Applicants have traversed by arguing that both 21-22 are withdrawn from consideration. groups are closely related, and that the searches would be co-extensive. Applicants' argument is not without merit; if Group I (now Group III) is determined to be novel in its present form, then novelty would likely accrue to the Group II claims. However, in the event that Group I (now Group III) is not novel in its present form, addititional searching would have to be undertaken to examine the Group II claims. Accordingly, in the event that Group III (or Group IV) is determined to be novel in its present form, or in amended form, there is a significant possibility that Group II would be rejoined therewith; certainly Of course, any limitations that have the matter would have to be revisited at that point. been introduced into the Group III (or Group IV) claims would have to be introduced into the Group II claims prior to rejoining.

In view of the change of examiners, the restriction requirement is revised as set forth below.

*

Restriction to one of the following inventions is required under 35 U.S.C. §121 (the

numbering begins with "III" to avoid conflict with any previous groupings):

III. Claims 1, 2, 9-13, 18, 20, 23, 24, drawn to a method of analysis, with the proviso that capping steps are excluded.

IV. Claims 3-13, 18-20, 23, 24, drawn to a method of analysis in which a capping step is mandated.

The claimed inventions are distinct.

Group IV requires a capping step, whereas Group III does not. Accordingly, these two groups are distinct. However, in the event that Group III is elected, and claims therein found allowable, it is quite possible that novelty would accrue to the Group IV invention. Regardless of which of the two groups (Group III or IV) is elected, the possibility of rejoining the other group (of the two) is not precluded by the fact of initial restriction. Given the relateness of the two inventions, one could argue that the examiner should provide at least one reference which would be applicable to one of the two groups but not the other. For the time being, it is asserted that justification exists for the grouping of claims set forth above.

Applicant is advised that for the response to this requirement to be complete, an election of the invention to be examined must be indicated, even if the requirement is traversed (37 C.F.R. 1.143).

Applicant is reminded that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

Serial No. 09/806,564 Art Unit 1653

In addition to the foregoing, applicants are required under 35 U.S.C. §121 to elect various species as set forth below.

In the event that group III is chosen for initial examination, election of each of the following is required:

- (a) a first cleavage agent (e.g., cyanogen bromide or trypsin)
- (b) a second cleavage agent (e.g., cyanogen bromide or trypsin)
- (c) a specific solid phase support (e.g., DITC glass or polystyrene isothiocyante) that is used to isolate the peptide fragments
- (d) the bonding of the peptide fragments to the solid phase support is <u>one</u> of the following:
 - (i) bonding of the peptide at its C-terminus, or (ii) bonding of the peptide at its N-terminus.

In the event that group IV is chosen for initial examination, election of each of the following is required:

- (a) a first cleavage agent (e.g., cyanogen bromide or trypsin);
- (b) a second cleavage agent (e.g., cyanogen bromide or trypsin);
- (c) a "first" capping agent (e.g., iodoacetate or phenylisocyantate);
- (d) a "second" capping agent (e.g., trimethylsilylchloride or acetic anhydride);
- (e) a specific functional group in the peptide that is capped (e.g., the *epsilon*-amino group of lysine);

- (f) a specific solid phase support (e.g., DITC glass or polystyrene isothiocyante) that is used to isolate the peptide fragments;
- (g) the bonding of the peptide fragments to the solid phase support is <u>one</u> of the following:
 - (i) bonding of the peptide at its C-terminus, or (ii) bonding of the peptide at its N-terminus.

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a generic claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are witten in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a).

Should applicant traverse on the ground that the species are not patentable distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. §103 of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is 703-308-3213. The examiner can normally be reached Monday-Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, can be reached at (703) 308-2923. The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

DAVID LUKTON
PATENT EXAMINER
GROUP 1900